The acquisition aims to integrate icometrix’s AI-powered neurological analysis platform with GE HealthCare’s MRI systems to meet growing demand in Alzheimer’s disease monitoring.
GE HealthCare has entered into an agreement to acquire icometrix, a company that provides AI-powered brain imaging analysis for neurological disorders. The move is intended to strengthen GE HealthCare’s neurology portfolio and meet the increasing demand for MRI in personalized treatment planning, particularly for Alzheimer’s disease.
The planned acquisition will integrate the icometrix icobrain platform with GE HealthCare’s MRI systems to create a more seamless workflow for clinicians. The platform includes icobrain aria, which has US Food and Drug Administration 510(k) clearance as a computer-aided detection and diagnosis solution for identifying amyloid-related imaging abnormalities (ARIA), known side effects of new anti-amyloid Alzheimer’s therapies. As these treatments become more common, the need for frequent MRI exams to monitor patients for potential brain swelling and microbleeds is expected to rise.
“This effort marks a pivotal step in our journey to advance precision care in neurology,” says Roland Rott, president and CEO, Imaging at GE HealthCare, in a release. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”
Workflow Integration and Multi-Vendor Support
GE HealthCare plans to expand patient access to the icobrain aria solution across all vendor MRI systems through both commercial distribution and clinical integration. The solution identifies both forms of ARIA—ARIA-E and ARIA-H—from MR scans and performs longitudinal analysis to track their occurrence over time. This provides radiologists with tools for monitoring patients throughout their treatment.
By integrating this solution with its own MR systems and technologies, such as AIR x Brain, AIR Recon DL, and SONIC DL 3D, GE HealthCare expects to optimize workflow and help clinicians manage the increased scan volume associated with new Alzheimer’s treatments.
“Our anticipated acquisition of icometrix and its icobrain solutions supports our goal to help clinicians deliver high-quality, timely care to meet this increased demand in MR technology,” says Kelly Londy, president and CEO, MR, GE HealthCare, in a release.
The icometrix suite of solutions also includes tools to help clinicians quantify brain MR scans over time for other disorders, including multiple sclerosis, dementia, epilepsy, and traumatic brain injury.
The transaction is subject to regulatory approvals and other customary closing conditions. Financial details have not been disclosed.
ID 316441842 © GRAPHIQUENOIR | Dreamstime.com
